利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2461 条记录 (耗时 0.031 秒)

    PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LUNG CANCER COMPRISING GLUCOCORTICOID-BASED COMPOUND
    4.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LUNG CANCER COMPRISING GLUCOCORTICOID-BASED COMPOUND 审中-公开

    公开(公告)号：US20190201416A1

    公开(公告)日：2019-07-04

    申请号：US15772714

    申请日：2016-11-02

    申请人： AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

    发明人： Sang-Min JEON

    IPC分类号： A61K31/573 ,  A61K31/436 ,  A61K31/404 ,  A61P35/00

    CPC分类号： A61K31/573 ,  A61K31/404 ,  A61K31/436 ,  A61P35/00

    摘要： Provided is a composition for treating or ameliorating lung cancer including a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 and LKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. Further, the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.

    PHARMACEUTICAL COMBINATIONS COMPRISING A PI3K INHIBITOR FOR THE TREATMENT OF CANCER
    9.
    发明申请
    PHARMACEUTICAL COMBINATIONS COMPRISING A PI3K INHIBITOR FOR THE TREATMENT OF CANCER 审中-公开

    公开(公告)号：US20180353495A1

    公开(公告)日：2018-12-13

    申请号：US16106345

    申请日：2018-08-21

    申请人： Novartis AG

    发明人： Cristian MASSACESI ,  Marie-Caroline GERMA

    IPC分类号： A61K31/4439 ,  A61K31/436 ,  A61K31/5685 ,  A61K45/06

    CPC分类号： A61K31/4439 ,  A61K31/436 ,  A61K31/5685 ,  A61K45/06 ,  A61K2121/00 ,  A61K2300/00

    摘要： A pharmaceutical combination comprising: (a) an alpha-isoform specific phosphatidylinositol-3-kinase inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) an mTOR inhibitor and (c) exemestane or any pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the preparation of a medicament for the treatment or prevention of a proliferative disease; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.